Julian Blagg

List of Publications by Year in descending order

41 papers	2,538 citations	236612 25 h-index	276539 41 g-index
43 all docs	43 docs citations	43 times ranked	4366 citing authors

#	Article	IF	Citations
1	C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays. European Journal of Medicinal Chemistry, 2019, 177, 316-337.	2.6	12
2	De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder. American Journal of Human Genetics, 2019, 104, 709-720.	2.6	41
3	Ligand discrimination between active and inactive activation loop conformations of Aurora-A kinase is unmodified by phosphorylation. Chemical Science, 2019, 10, 4069-4076.	3.7	8
4	High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Molecular Cancer Therapeutics, 2019, 18, 1696-1707.	1.9	24
5	Design, Synthesis and Characterization of Covalent KDM5 Inhibitors. Angewandte Chemie - International Edition, 2019, 58, 515-519.	7.2	22
6	Privileged Structures and Polypharmacology within and between Protein Families. ACS Medicinal Chemistry Letters, 2018, 9, 1199-1204.	1.3	16
7	Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4-d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N²-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N⁸-neopentylpyrido[3,4 (BOS172722). Journal of Medicinal Chemistry, 2018, 61, 8226-8240.	2.9	24
8	Donated chemical probes for open science. ELife, 2018, 7, .	2.8	80
9	Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer. Cell Chemical Biology, 2018, 25, 1359-1371.e2.	2.5	17
10	Evaluation of APOBEC3B Recognition Motifs by NMR Reveals Preferred Substrates. ACS Chemical Biology, 2018, 13, 2427-2432.	1.6	10
11	Assessing histone demethylase inhibitors in cells: lessons learned. Epigenetics and Chromatin, 2017, 10, 9.	1.8	40
12	Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy. British Journal of Cancer, 2017, 116, 1166-1176.	2.9	23
13	Dynamic Equilibrium of the Auroraâ€...A Kinase Activation Loop Revealed by Singleâ€Molecule Spectroscopy. Angewandte Chemie - International Edition, 2017, 56, 11409-11414.	7.2	37
14	Dynamic Equilibrium of the Auroraâ€...A Kinase Activation Loop Revealed by Singleâ€Molecule Spectroscopy. Angewandte Chemie, 2017, 129, 11567-11572.	1.6	5
15	Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. Cancer Cell, 2017, 32, 9-25.	7.7	183
16	Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution. Xenobiotica, 2017, 47, 771-777.	0.5	6
17	Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. ELife, 2016, 5, .	2.8	69
18	Mapping the 3D structures of small molecule binding sites. Journal of Cheminformatics, 2016, 8, .	2.8	13

#	Article	IF	Citations
19	2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. ACS Medicinal Chemistry Letters, 2016, 7, 573-578.	1.3	39
20	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. Journal of Medicinal Chemistry, 2016, 59, 3671-3688.	2.9	29
21	Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. Journal of Medicinal Chemistry, 2016, 59, 9337-9349.	2.9	86
22	Characterization of Hedgehog Acyltransferase Inhibitors Identifies a Small Molecule Probe for Hedgehog Signaling by Cancer Cells. ACS Chemical Biology, 2016, 11, 3256-3262.	1.6	43
23	Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1443-1451.	1.0	34
24	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. Journal of Medicinal Chemistry, 2016, 59, 1078-1101.	2.9	89
25	8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1388-1409.	2.9	83
26	Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen. Journal of Medicinal Chemistry, 2015, 58, 1717-1735.	2.9	65
27	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance. Cancer Research, 2015, 75, 3340-3354.	0.4	27
28	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	3.9	698
29	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature Chemical Biology, 2015, 11, 973-980.	3.9	114
30	7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4203-4209.	1.0	13
31	Diverse Functionalization of Aurora-A Kinase at Specified Surface and Buried Sites by Native Chemical Modification. PLoS ONE, 2014, 9, e103935.	1.1	10
32	Chemical biology approaches to target validation in cancer. Current Opinion in Pharmacology, 2014, 17, 87-100.	1.7	36
33	Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1). Journal of Medicinal Chemistry, 2013, 56, 10045-10065.	2.9	72
34	Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells. Journal of Medicinal Chemistry, 2013, 56, 9122-9135.	2.9	70
35	Insights into Aurora-A Kinase Activation Using Unnatural Amino Acids Incorporated by Chemical Modification. ACS Chemical Biology, 2013, 8, 2184-2191.	1.6	39
36	Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2012, 55, 8721-8734.	2.9	61

#	Article	IF	Citations
37	Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate. Journal of Medicinal Chemistry, 2010, 53, 5213-5228.	2.9	80
38	Microwave-assisted synthesis of 4-amino-3,5-dihalopyridines. Tetrahedron, 2010, 66, 2398-2403.	1.0	8
39	Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5988-5993.	1.0	30
40	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Research, 2010, 70, 5963-5973.	0.4	96
41	Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Biochemical Journal, 2010, 427, 19-28.	1.7	86